Northwest Biotherapeutics (STU:NBYB) EPS (Basic) : €-0.06 (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Northwest Biotherapeutics EPS (Basic)?

Northwest Biotherapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was €-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.06.

Northwest Biotherapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was €-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.06.

Northwest Biotherapeutics's EPS without NRI for the three months ended in Sep. 2024 was €-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.07.

During the past 3 years, the average EPS without NRI Growth Rate was 23.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 32.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Northwest Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was 64.20% per year. The lowest was -12.50% per year. And the median was 29.60% per year.

Northwest Biotherapeutics EPS (Basic) Historical Data

The historical data trend for Northwest Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics EPS (Basic) Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.04

-0.60

0.19

-0.09

-0.06

Northwest Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.02	-0.01	-0.02	-0.02	-0.02

Northwest Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Northwest Biotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-57.403	-	0)	/	1119.191
	=	-0.05

Northwest Biotherapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-17.456	-	0)	/	1258.532
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.06

Northwest Biotherapeutics (STU:NBYB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Northwest Biotherapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (STU:NBYB) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

NWBO:USA

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics Headlines

No Headlines